6-K - IVA - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Forthe Month of April 2022

Commission File Number: 001-39374

Inventiva S.A.

(Translation of registrant’s name intoEnglish)

50 rue de Dijon

21121 Daix France

+333 80 44 75 00**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

On April 28, 2022, Inventiva S.A. issued a press release (the “Press Release”) and a statement of total voting rights and shares forming the company’s share capital as of April 11, 2022 (the “Statement”).

A copy of the Press Release is furnished as Exhibit 99.1 and a copy of the Statement as Exhibit 99.2 to this Report on Form 6-K.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated April 28, 2022.
99.2	Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inventiva S.A.
Date: April 28, 2022	By:	/s/<br>Frédéric Cren
		Name	Frédéric Cren
		Title:	Chief Executive Officer

Exhibit 99.1

PRESS RELEASE

CombinedGeneral Meeting of May 19, 2022

Availabilityof the preparatory documents

Daix(France), Long Island City (New York, United States), April 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 19, 2022.

Shareholders are invited to participate in the annual Combined General Meeting that will be held on May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France).

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n°43 of April 11, 2022 and a translation was filed with the Securities and Exchange Commission on April 11, 2022.

Information and documents pertaining to the Combined General Meeting are available in the Company's website (www.inventivapharma.com, section "Investors" / "Shareholder Meetings").

In accordance with articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders for the purpose of general meetings will be available at the Company's registered office, 50, Rue de Dijon, 21121 Daix, the fifteenth day prior to the Combined General Meeting.

Documents listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva’s website mentioned above as from today, the twenty-first day that precedes the General Meeting.

In accordance with applicable regulatory provisions:

·	any<br> shareholder holding registered shares may, up to the fifth day, inclusive, prior to the General<br> Meeting, request these documents to be sent by the Company. For shareholders holding bearer<br> shares, the exercise of this right is subject to the submission of a shareholding certificate<br> delivered by their financial intermediary;
·	any<br> shareholder may consult these documents at the Company's registered office by sending a request<br> by e-mail to the following electronic address: Inventiva_AG@inventivapharma.com.
---	---

AboutInventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

PRESS RELEASE

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

ImportantNotice

Thispress release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-lookingstatements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva’s pre-clinicalprograms and clinical trials, pipeline and preclinical and clinical development plans, future activities, expectations, plans, growthand prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, withoutlimitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”,and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectationsand other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailingas of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance orfuture events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and maydepend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates thatthe clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated,that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or itspartners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipatedfuture results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors,including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva hasincurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue fromproduct sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependenton the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates,preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinicaltrials may not support Inventiva's product candidate claims, Inventiva may encounter substantial delays in its clinical trials orInventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retentionof patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible bymultiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other propertiesthat could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competitionand Inventiva’s business, and preclinical studies and clinical development programs and timelines, its financial condition andresults of operations could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as theconflict between Russia and Ukraine, which could delay the initiation, enrolment and completion of Inventiva’s clinical trialson anticipated timelines or at all. Given these risks and uncertainties, no representations are made as to the accuracy or fairness ofsuch forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speakas of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

PRESS RELEASE

Pleaserefer to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des MarchésFinanciers on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securitiesand Exchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.

Allinformation in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and isunder no obligation to update or review the forward-looking statements referred to above.

Contacts

Inventiva<br><br> Frédéric Cren <br><br>Chairman & CEO<br><br> info@inventivapharma.com<br><br> +33 3 80 44 75 00	Brunswick Group <br><br> Yannick Tetzlaff / <br><br> Tristan Roquet Montegon / <br><br> Aude Lepreux <br><br> Media relations <br><br> inventiva@brunswickgroup.com <br><br> +33 1 53 96 83 83	Westwicke, an ICR Company<br> Patricia L. Bank<br> Investor relations<br> patti.bank@westwicke.com<br> +1 415 513-1284

Exhibit 99.2

PRESS RELEASE

Statement oftotal voting rights and shares forming the

company’sshare capital as of April 11, 2022

Article R.22-10-23 of the French Commercial Code

Market : Euronext Paris

ISIN code / Mnemo : FR0013233012 / IVA

Web site : www.inventivapharma.com

Date	Number of Shares<br> Outstanding	Total voting rights, <br> gross ^(1)^	Total voting rights,<br> net ^(2)^
April 11, 2022	40 873 551	52 801 409	52 741 093
^(1)^	The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
---	---
^(2)^	The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended, i.e. treasury shares (including shares purchased under the liquidity contract). It is released in order to ensure that the public is properly informed.
---	---

About Inventiva

PRESS RELEASE

Important Notice

This press releasecontains “forward-looking statements” within the meaning of thesafe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts,included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts andestimates with respect to Inventiva’s pre-clinical programs and clinical trials, pipeline and preclinical and clinical developmentplans, future activities, expectations, plans, growth and prospects ofInventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, and “continue”and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-lookingstatements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of thestatements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differmaterially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors thatare beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial resultswill be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidateswill receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reachedon their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performanceor achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventivais a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant lossessince inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventivawill require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development,regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinicaltrials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's productcandidate claims, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safetyand efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is anexpensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva'scontrol, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent theirregulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s business,and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materiallyand adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, whichcould delay the initiation, enrolment and completion of Inventiva’s clinical trials on anticipated timelines or at all. Given theserisks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts andestimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readersare cautioned not to place undue reliance on any of these forward-looking statements.

Please referto the Universal Registration Document for the year ended December 31, 2021 filed with the Autorité des Marchés Financierson March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities andExchange Commission on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.

All informationin this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligationto update or review the forward-looking statements referred to above.

PRESS RELEASE

Contacts

Inventiva<br> <br><br> Frédéric Cren Chairman & CEO<br><br> info@inventivapharma.com<br><br> +1 240 620 9175	Brunswick Group <br><br> Laurence Frost / <br><br> Tristan Roquet Montegon / <br><br> Aude Lepreux <br><br> Media relations <br><br> inventiva@brunswickgroup.com <br><br> +33 1 53 96 83 83	Westwicke, an ICR Company <br><br> Patricia L. Bank <br><br> Investor relations <br><br> patti.bank@westwicke.com <br><br> +1 415 513 1284